All In Biotech

Drug Trial Radar · NCT05093855

Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

A Multicenter, Open-label, Phase II Study to Explore Efficacy and Safety of BDB-001 Injection in Subjects With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Aug 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

41

Actual

Start

Aug 18, 2021

Primary completion

Aug 22, 2023

Study completion Aug 22, 2023

Sponsor

Sponsor type
Industry
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to explore whether BDB-001 Injection is effective and safe in the treatment of moderate to severe hidradenitis suppurativa(HS).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BDB-001 InjectionDrug

    Multiple IV infusions of BDB-001 Injection diluted in sodium chloride

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in International Hidradenitis Suppurativa Severity Score System (IHS4) score from Day 0 by time pointTime frame: Week 8

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Union Hospital Tongji Medical College Huazong University of Science and Technology

    Wuhan, Hubei, China

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Chinese Academy of Medical Sciences and Peking Union Medical College

    Nanjing, Jiangsu, China

  • The First Hospital of Jilin Universitv

    Changchun, Jilin, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Second Affiliated Hospital of Air Force Medical University

    Xi'an, Shaanxi, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

  • Huashan Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

  • Shanghai Skin Disease Hospital

    Shanghai, Shanghai Municipality, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.